Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
May 12, 2022 1 min read
Shares of Roche RHHBY were down 9.1% after it announced disappointing results from the phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer (NSCLC).
More Stories
These 6 Nasdaq-100 Stocks Jumped More Than 10% Friday
Why Lucid Stock Drove Higher Today
Price analysis 5/13: BTC, ETH, BNB, XRP, ADA, SOL, DOGE, DOT, AVAX, SHIB